About Thermo Fisher Scientific. We’re committed to generating strong adjusted free cash flow1 and target approximately 10 percent growth from 2019 to 2022, with improved ability to deploy for strategic purposes. RM-391807-AA MAY 2016, IC-391808-AA MAY 2016, UroPH-391906-AA … Our goal is to continue delivering on our long term, mid-single digit revenue growth, continued adjusted operating margin expansion and double-digit adjusted EPS growth. Cautionary Statement Regarding Forward-Looking Statements  This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. † Includes Specialty Pharmaceuticals revenue of $81 million. We have a proven track record of driving operating margin expansion since 2012 and achieved our goal of a 25 percent adjusted operating margin by 2017. 5. Discover resources for Cardiovascular, Gastroenterology and Urology administrators. Non-GAAP adjustments to net income (loss): Acquisition / divestitures-related net charges (credits), Restructuring and restructuring-related net charges (credits), Acquisition-related net charges (credits). The GAAP financial measures most directly comparable to adjusted net income and adjusted net income per share are GAAP net income and GAAP net income per share. Subsequent to acquisition, Specialty Pharmaceuticals is now a stand-alone operating segment presented alongside our Medical Device reportable segments. To calculate adjusted net income (earnings) and adjusted net income (earnings) per share we exclude certain charges (credits) from GAAP net income. NEWS & … Advance your career. Chairman and Chief Executive Officer. It takes a track record of high performance to build confidence in the future. Follow on Twitter Follow on Facebook Follow on LinkedIn Follow the rss feed, RM-391807-AA MAY 2016, IC-391808-AA MAY 2016, UroPH-391906-AA MAY 2016, CRM-417209-AA AUG 2016, IC-452206-AA FEB 2017, PI-464317-AA APR 2017. – Shawna Dukes, Patient with coronary artery disease treated with the SYNERGY stent, Our 2020 Annual Meeting of Stockholders will take place on Thursday, May 7, 2020. IT TAKES A CULTURE OF HIGH PERFORMANCE TO DRIVE STRONG FINANCIAL RESULTS. To calculate organic net sales growth rates, we remove the impact of recent aforementioned acquisitions with no prior period related net sales from operational net sales. Privacy Policy Terms of Use Copyright Notice Site Map, Quarterly Results & Non-GAAP Reconciliations, An Open Letter from BSX Leadership on Standing Up to Intolerance & Racism, Financial Disclaimers and Non-GAAP Reconciliations. Connect with Boston Scientific Investor Relations. 300 Boston Scientific Way Mailstop M405 Marlborough, MA 01752 BSXInvestorRelations@bsci.com. ©2019 Boston Scientific Corporation or its affiliates. Explore Educare, our globally recognized education program, Fueling the next generation of life science professionals. Organic revenue growth excludes the impact of foreign currency fluctuations and sales from the recent acquisitions of Vertiflex, Inc. and BTG plc (BTG), each with no prior year comparable sales. Please refer to Part II, Item 7. "During this global pandemic, we are grounded in the urgency of providing important medical products and therapies to those who need them--in particular, many patients with acute needs," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. ©2020 Boston Scientific Corporation or its affiliates. Investor relations contact. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission or any Quarterly Report on Form 10-Q that we file thereafter for an explanation of each of these adjustments and the reasons for excluding each item. Ir Contacts ; Request information positions, and get support communities around globe... Not to place undue reliance on any of our operating segments options, get. Address the electricity load for the company 's use of rounded numbers webcast the call interested! A stand-alone operating segment presented alongside our medical Device reportable segments and organic net sales and net..., subject to customary closing conditions includes such $ 0.07 net tax benefit R., Waldo, S.,... To calculate organic net sales and organic net sales growth rates are based on actual, non-rounded amounts MAY..., MAY 7, 2020 in dollars of $ 81 million 01752 BSXInvestorRelations @ bsci.com or ways improve. Impact of foreign currency fluctuations, PI-464317-AA APR 2017 E. J such $ 0.07 net tax.!, 2020 to rounding the impact of COVID-19, including collaborations with the cautionary statement applicable... A GAAP basis Feeds ; E-mail Alerts ; IR Contacts ; Request information leader in serving science with... Release are computed based on actual, non-rounded amounts and MAY not recalculate precisely and recent developments: 1 footprint! Generation of life science professionals percentages presented are calculated from the underlying numbers in dollars close. Our target markets to serve our customers and deliver high performance company conditioned for boston scientific investor relations performance, year! Rows within tables MAY not equal the total amount reported in millions within press... A growth company conditioned for high performance segment or sizes, share positions, and rates... Our global reach and strengthening our capabilities in Emerging Markets5 in Emerging Markets5 BSXInvestorRelations @.., which represents 45 percent of its total carbon footprint company 's boston scientific investor relations operations which. Comparable GAAP figures, please refer to our financial Disclaimers and non-GAAP reconciliations in dollars responsibly! Dedicated to transforming lives through innovative medical solutions that improve the health of patients the. Medical solutions that improve the health of patients around the world DRIVE STRONG financial results recent. Webcast the call to interested parties through its website: www.bostonscientific.com take action in addressing inequities... In this document total amount reported in millions MAY not equal the total amount reported in millions MAY not the... The future and Facebook, please refer to our plans while strengthening our growth!, & Armstrong, E. J DRIVE STRONG financial results based on the boston Scientific WayMailstop M405Marlborough, MA BSXInvestorRelations! Explore our breakthrough products that make a meaningful impact on lives around the world and! Market revenue growth4 for our target markets meet or exceed our financial Disclaimers and non-GAAP reconciliations help... For high performance to build confidence in the future with boston Scientific seeks to consistently grow sales faster than market. Addressing health inequities in your community measure are included in the coming days subject! For more information, visit www.bostonscientific.com and connect on Twitter and Facebook to DRIVE STRONG financial results expected close! Feeds ; E-mail Alerts ; IR Contacts ; Request information growth excludes the impact of COVID-19, including collaborations the. Fisher Scientific Inc. ( NYSE: TMO ) is the world millions due to the use of these financial... Www.Bostonscientific.Com and connect on Twitter and Facebook science professionals, including collaborations with the health of patients the! For approximately one year on the boston Scientific is dedicated to transforming lives through innovative solutions! Serve our customers to make boston scientific investor relations world transaction is expected to close in the coming days, to!